Changing Front-Line Therapy In Mds And Aml

Changing front-line therapy in MDS and AML

VJHemOnc – Video Journal of Hematology & HemOnc

The frontline treatment strategy for newly diagnosed AML

VJHemOnc – Video Journal of Hematology & HemOnc

MDS/AML Overlap and Novel Therapies with Dr. Naval Daver

Front-line treatment options for HR-MDS: can we move past azacitidine?

VJHemOnc – Video Journal of Hematology & HemOnc

Novel Therapies in Myeloid Neoplasms

LurieCancerCenter

Treating AML with MDS-related Changes

AML Treatment Challenges Who, When, and How

Venetoclax + Azacitidine in Frontline AML Management

Targeted Oncology

Treatment of AML With Myelodysplasia-Related Changes

The Role of BMT in Treatment-Related MDS and AML

Expanding treatment options for AML to patients with MDS

VJHemOnc – Video Journal of Hematology & HemOnc

AML: A Case of Myelodysplasia-Related Changes

Targeted Oncology

Beat AML Trial to Expand into MDS Therapy

Blood Cancers Today

Impact of Targeted Therapies on Treatment of MDS and AML

Precision Medicine in MDS and AML

MDS Foundation, Inc.

Beyond current treatment options in frontline therapy, what future changes may lie ahead?

MediCom Oncology

Virtual Series Session 3: Myelodysplastic Syndromes and Acute Myeloid Leukemia

Leukemia Research Foundation

A Master Class on Building Better Therapy for AML

PeerView Oncology

Venetoclax and magrolimab for treatment of AML and MDS

VJHemOnc – Video Journal of Hematology & HemOnc

CAR T Cell Therapy in MDS/AML

MDS Foundation, Inc.